NasdaqGS:ZVRAPharmaceuticals
Zevra Therapeutics (ZVRA) Valuation Check As New MIPLYFFA Data And EMA Filing Draw Fresh Attention
Zevra Therapeutics (ZVRA) is back on investors’ radar after presenting new real world and clinical data on its approved Niemann Pick disease type C therapy MIPLYFFA at the 22nd Annual WORLDSymposium, alongside progress in Europe.
See our latest analysis for Zevra Therapeutics.
Zevra’s share price has been choppy recently, with a 1 day share price return of 6.49% and a 7 day share price return of 5.64% around the WORLDSymposium data. Its 1 year total shareholder return of 6.09% sits against a...